AstraZeneca to buy Alexion for $39 billion to expand in immunology
Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs, Trend reports citing Reuters.
The deal comes in a week that AstraZeneca said it was conducting further research to confirm whether its COVID-19 vaccine could be 90% effective, potentially slowing its rollout, and as a rival shot from Pfizer was launched in Britain and approved for use in the United States.
The British company said on Saturday that Alexion shareholders would receive $60 in cash and about $115 worth of equity per share - either in AstraZeneca’s UK-traded ordinary shares or in dollar-denominated American Depositary Shares.
Based on a reference average ADR price of $54.14, that implies a total price of $175 per share. Alexion shares closed at around $121 apiece on Friday.
“It is a tremendous opportunity for us to accelerate our development in immunology, getting into a new segment of disease, a new segment of physicians, and patients we haven’t been able to cover so far,” AstraZeneca Chief Executive Pascal Soriot told a media call.